PT

Poltreg SAWSE Poltreg Stock Report

Last reporting period 30 Sep, 2023

Updated 25 Oct, 2024

Last price

Market cap $B

0.066

Micro

Exchange

XWAR - Warsaw Stock Exchange

PTG.WA Stock Analysis

PT

Uncovered

Poltreg SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-38/100

Low score

Market cap $B

0.066

Dividend yield

Shares outstanding

4.66 B

PolTREG SA develops and commercializes patented TREG methods. The company is headquartered in Gdansk, Woj. Pomorskie and currently employs 11 full-time employees. The company went IPO on 2021-11-23. The firm conducts research in the field of autoimmunological diseases. The firm works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The firm works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The firm is developing its own research center, which is intended as a basic location for conducting future research activities.

View Section: Eyestock Rating